Drug news
Trial comparing Xience V (Abbott) with Endeavor Resolute (Metronic) shows non-inferiority for PCI patients
The TWENTE clinical trial, which compared two second generation drug-eluting stents � the Endeavor Resolute zotarolimus stent from Medtronic and the Xience V everolimus-eluting stent from Abbott � established non-inferiority between the two stents as measured by the primary endpoint: target vessel failure (TVF) at one year. Both stents also demonstrated low rates of stent thrombosis. TVF at one year occurred in 8.2% of patients for the zotarolimus-eluting stent, and in 8.1% of patients for the everolimus-eluting stent (p=0.94). For the components of the primary endpoint, there were also no significant differences: cardiac death (1.0% vs. 1.4%, p=0.46), target vessel-related myocardial infarction (4.6% vs. 4.6%, p=0.98), and clinically driven target vessel revascularization (3.3% vs. 2.7%, p=0.53). TWENTE showed similar and � considering the complexity of the patient population and the lesion characteristics � relatively low one-year rates of definite-plus-probable stent thrombosis for the zotarolimus and everolimus-eluting stents (0.86% and 1.16%, respectively). TWENTE also showed a low definite one-year stent thrombosis rate for zotarolimus and everolimus-eluting stents (0.58% and 0%, respectively). Zotarolimus-eluting stents are non-inferior to everolimus-eluting stents in terms of safety and efficacy for treating 'real-world' patients with a vast majority of complex lesions and 'off-label' indications, according to lead researcher Clemens von Birgelen, Professor of Cardiology at University of Twente in the Netherlands. Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.